Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study [PDF]
Clinical OphthalmologyDebdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Krishnendu Nandi,2 Dinesh Rungta,1 Ranabir Bhattacharya1 1Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, WB, India; 2Vitreo-retina Services ...
Chakraborty D +7 more
doaj +2 more sources
Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion [PDF]
BMC OphthalmologyObjective To compare the effectiveness and safety of three loading doses of bevacizumab and ranibizumab for macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods This retrospective study included 49 patients with BRVO. The patients were
Sibel Coşkun Akdemir +1 more
doaj +2 more sources
ClinicoEconomics and Outcomes Research, 2015 Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Régnier SA +3 more
doaj +3 more sources
International Journal of Ophthalmology, 2014 AIM:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).METHODS:The Cochrane Central Register of Controlled Trials (CENTRAL)
Jun-Kang Si +9 more
doaj +2 more sources
Canadian Medical Association Journal, 2011 Ranibizumab is a recombinant, monoclonal antibody fragment that inhibits vascular endothelial growth factor (known as a VEGF-A inhibitor).1 Because it costs about 10 times more than bevacizumab,2 an anti-VEGF agent approved for intravenous use in metastatic colon cancer, ophthalmologists may ...
Jason, Noble, Varun, Chaudhary
openaire +2 more sources
Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.
PLoS ONE, 2022 PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama +7 more
doaj +1 more source
Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis [PDF]
International Journal of Ophthalmology, 2017 AIM: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro.
Wei Wang +4 more
doaj +1 more source
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome [PDF]
International Journal of Ophthalmology, 2016 AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis.
Patrick J Chiam +3 more
doaj +1 more source
Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]
, 2020 Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery +30 more
core +4 more sources
One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study [PDF]
International Journal of Ophthalmology, 2018 AIM: To assess the effectiveness and safety of ranibizumab 0.5 mg in Taiwanese patients with polypoidal choroidal vasculopathy (PCV) by performing a retrospective exploratory subgroup analysis of the REAL study.
San-Ni Chen +8 more
doaj +1 more source